Browse > Article

Screening of Medicinal Plants for Development of Functional Food Ingredients with Anti-Obesity  

Kim, Yeong-Jin (Department of Microbiology and Immunology, College of Medicine, Pusan National University)
Kim, Bo-Hye (Department of Microbiology and Immunology, College of Medicine, Pusan National University)
Lee, Sun-Yi (Department of Microbiology and Immunology, College of Medicine, Pusan National University)
Kim, Min-Soo (Korea Research Institute of Bioscience and Biotechnology)
Park, Chan-Sun (Korea Research Institute of Bioscience and Biotechnology)
Rhee, Moon-Soo (Korea Research Institute of Bioscience and Biotechnology)
Lee, Kang-Hyun (Korea Research Institute of Bioscience and Biotechnology)
Kim, Dong-Seob (School of Applied and Life Science, College of Natural Resources and Life Science, Pusan National University)
Publication Information
Applied Biological Chemistry / v.49, no.3, 2006 , pp. 221-226 More about this Journal
Abstract
In order to search anti-obesity agents, the methanol extracts of 155 herbal medicines were screened using with pancreatic lipase, which is involved in conversion of triglycerol to fatty acid. Among the tested medicinal plants, methanol extracts of Amsonia elliptica, Arecae pericarpium, Biota orientalis, Cinnamomum cassia, Curcuma aromatia, Elsholtzia ciliate, Glycyrrhiza uralensis, Mucunae Caulis, Rhus javanica, and Rubus coreanus showed potent inhibition at final concentration of $200\;{\mu}g/ml$ on pancreatic lipase activity. All of them were extracted into chloroform fraction. The relative inhibitory activities against pancreatic lipase by orlistat, the chloroform fraction of Arecae pericarpium and Cinnamomum cassia were 89, 80 and 80%, respectively. These results demonstrated that the screened medicinal plants could be develop as the effective lipase inhibitors in preventing and ameliorating obesity of human beings.
Keywords
Pancreatic lipase inhibitor; medicinal herbs; obesity; modulating agent;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Diehl, A. K. (1991) Epidemiology and natural history of gallstone disease. Gastroenterol. Clin. N. Am. 20, 1-19
2 Hadvay, P., Lengsfeld H. and Wolter H. (1988) Inhibition of pancreatic lipase in vitro by covalent inhibitor tetrahydrolipstatin. Biochem. J. 256, 357-361   DOI
3 Grundy, S. M. (1999) Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am. J. Cardiol. 83, 25F-29F
4 Bray, G. A. and Popkin B. M. (1999) Dietary fat affects obesity rate. Am. J. Clin. Nutr. 70, 572-573   DOI
5 Rexrode, K. M., Manson J. E. and Hennekens C. H. (1996) Obesity and cardiovascular disease. Curr. Opin. Cardiol. 11, 490-495   DOI
6 Wada, K. and Ikeda.Y. (1998) Longitudinal studies to determine the effect of body fat rate reduction on blood pressure. J. Med. Syst. 22, 19-25   DOI   ScienceOn
7 Alberti, K. G. and Zimmet P. Z. (1988) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 13, 539-353
8 Drent, M. L., Larsson I., William-Olsson T., Quaade F., Czubayko F., Von Bergmann K., Strobel W., Sjotro L. and Van der Veen E. A. (1995) Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int. J. Obes. 19, 221 -226
9 Bitou, N., Nimomiya M., Tsjita T. and Okuda H. (1999) Screening of lipase inhibitors from marine algae. Lipids 34, 441-445   DOI   ScienceOn
10 Freedman, D. S., Serdula M. K., Perey C. A. and Whitle L. (1997) Obesity levels of lipids and glucose, and smoking among Navajo adolescents. J. Nutr. 127, 2120S-2127S
11 Peter, C. and Williams G. (2001) Drug treatment of obesity: from past failures to future successes. Br. J. Clin. Pharmacol. 51, 135
12 Larsson, B., Bjorntorp P. and Tibblin G. (1981) The health consequences of moderate obesity. Int. J. Obes. Relat. Metab. Disord. 5, 97-106
13 Borgstom, B. (1986) Luminal digestion of fat. In The exocrine pancreas: biology, pathobiology, and disease. (1st ed.). pp. 361-373, Raven Press, New York
14 Bray, G. A. and Popkin B. M. (1998) Dietary fat intake dose affect obesity. Am. J. Clin. Nutr. 68, 1157-1173   DOI
15 Shimura, S., Tsuzuki W., Itho Y., Kobayashi S. and Suzuki T. (1994) Inhibitory effect of tannin fraction Cassia mimosoides L. var. nomame makino on lipase activity. Nippon Shokuhin Kogyo Gakkaishi. 41, 561-564   DOI   ScienceOn
16 Zapf, J., Schoenole E. W., Waldvogel M., Sand M. and Froesch E. R. (1981) Effect of trypsin treatment of rat adipocyte on biological effects and binding of insulin and insulin-like growth factors: Further evidence for the action of insulin-like growth factors through the insulin receptor. Eur. J. Biochem. 133, 605-609
17 Hauptman, J. B., Jeunet F. S. and Hartmann D. (1992) Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am. J. Clin. Nutr. 55, 309S -313S
18 Hadvary, P., Sidlerj W., Meister W., Vetter W. and Wolfer H. (1991) The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase. J. Biol. Chem. 266, 2021-2027
19 Yamamoto, M., Shimura S., Iyoh Y., Egawa M. and Ionue S. (2000) Anti-obesity effects of lipase inhibitor CT-II, an extract from edible herbs, Nomame Herba, on rats fed a high-fat diet. Int. J. Obesity 24, 758-764   DOI   ScienceOn
20 World Health Organization Consultation on Obesity. (1998) Obesity: Preventing and Managing the Global Epidemic. World Health Organization: Geneva
21 Sjostrom, L., Rissanen A., Andersen T., Boldrin M., Golay A. and Koppeschaar H. P. F. (1998) Randomized placebocontrolled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 352, 167-172   DOI   ScienceOn
22 Flegal, K. M., Carroll M. D., Ogden C. L. and Johnson C. L. (2002) Prevalence and trends in obesity among U.S. adults, 1999-2000. JAMA 288, 1723-1727   DOI